The telehealth company Hims & Hers put out a Super Bowl ad that skimped on clarifying that its compounded semaglutide ...

The Hims brand has primed people to view both their everyday health and the natural-aging processes as problems that can be ...

CNBC's Brandon Gomez joins 'Squawk on the Street' to break down the controversy around Hims & Hers Super Bowl ads.

Two healthcare stocks in the white-hot weight-loss segment tanked on Monday as one of their rivals zoomed higher. The ...

Hims & Hers' future growth is expected from personalized solutions, with potential to expand the subscriber base by millions.

Compounded weight-loss medications such as those promoted in the Hims & Hers commercial aren’t approved by the FDA.

The next FDA Commissioner could solve two big problems with one powerful policy: encourage independent testing of both ...

Hims & Hers' “Sick of the System” spot not only generated the highest engagement of all pharma-related ads that aired during ...

Hims & Hers, a San Francisco-headquartered telehealth company, ran its controversial Super Bowl commercial despite multiple ...

Ozempic and Wegovy maker Novo Nordisk placed a print ad responding to the Super Bowl spot from competitor Hims & Hers.

Hims & Hers offers a copycat of the blockbuster weight-loss drug at a fraction of the cost. But it might be a short-lived ...

Shares of Hims & Hers rose 5.2% Monday after the telehealth provider ran an advertisement on Super Bowl Sunday highlighting the company's efforts to fight the obesity epidemic in America. But Heard on ...